Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ: Androgen receptor term in the hormone estrogen receptor-negative cancer of the breast

Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ: Androgen receptor term in the hormone estrogen receptor-negative cancer of the breast

Bieche I, Parfait B, Tozlu S, Lidereau Roentgen, Vidaud M: Quantitation away from androgen receptor gene term for the sporadic breast tumors by real-day RT-PCR: proof that MYC is an AR-controlled gene. Carcinogenesis. 2001, twenty-two (9): 1521-1526. /carcin/22.9.1521.

Bratthauer GL, Lininger RA, Son YG, Tavassoli FA: Androgen and you will estrogen receptor mRNA updates inside the apocrine carcinomas. Diagn Mol Pathol. 2002, eleven (2): 113-118. 9606-200206000-00008.

Gatalica Z: Immunohistochemical analysis out-of apocrine nipple lesions. Uniform over-term off androgen receptor followed by the increasing loss of estrogen and you may progesterone receptors for the apocrine metaplasia and you will apocrine carcinoma into the situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.

Am J Clin Pathol

Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S: Androgen receptors inside the operable cancer of the breast: relation to almost every other steroid hormones receptors, correlations to help you prognostic things and you can predictive worthy of to have aftereffect of adjuvant tamoxifen medication. Eur J Surg Oncol. 1992, 18 (2): 112-118.

Bayer-Garner IB, Smoller B: Androgen receptors: an excellent marker to improve sensitivity getting pinpointing breast cancer when you look at the epidermis metastasis away from not familiar pri, thirteen (2): 119-122. /modpathol.3880021.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic craft and you can clinical effects. J Clin Oncol. 2000, 18 (5): 1135-1149.

Pang ST, Flores-Morales A good, Skoog L, Chuan YC, Nordstedt G, Pousette A: Control regarding matrix metalloproteinase 13 phrase of the androgen inside prostate disease. Oncol Representative. 2004, eleven (6): 1187-1192.

Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.

Schippinger W, Regitnig P, Dandachi Letter, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Assessment of your prognostic requirement for androgen receptor phrase for the metastatic cancer of the breast. Virchows Arch. 2006, 449 (1): 24-30. /s00428-006-0213-6.

Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, Gilks CB: Testing of interlaboratory variation on the immunohistochemical determination away from the hormone estrogen receptor position using a cancer of the breast structure microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.

Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Examination of matrix metalloproteinases in addition to their inhibitors inside the breast cancer. Br J Malignant tumors. 2007, 96 (6): 903-911. /sj.bjc.6603666.

Narita D, Raica Yards, Suciu C, Cimpean A great, Anghel A: Immunohistochemical expression away from androgen receptor and you can prostate-specific antigen inside cancer of the breast. Folia Histochem Cytobiol. 2006, 49 (3): 165-172.

Egeblad M, Werb Z: The fresh attributes on matrix metalloproteinases when you look at the disease evolution. Nat Rev Cancers. 2002, dos (3): 161-174. /nrc745.

Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–towards main phase regarding cancer?. Disease Telephone. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.

Manes S, Llorente Yards, Lacalle RA, Gomez-Mouton C, Kremer L, Mira Elizabeth, Martinez Air cooling: The brand new matrix metalloproteinase-nine regulates new insulin-such as for example development basis-caused autocrine response inside the DU-145 carcinoma cells. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..

Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M: Discharge of an attack promoter E-cadherin fragment by matrilysin and stromelysin-1. J Phone Sci. 2001, 114 (Pt 1): 111-118.

Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] expression chooses having tissue with just minimal sensitiveness to apoptosis. Neoplasia. 2001, 3 (6): 459-468. /sj.neo.7900190.


Stetler-Stevenson WG: Matrix metalloproteinases when you look at the angiogenesis: a moving target having healing intervention. J Clin Purchase. 1999, 103 (9): 1237-1241. /JCI6870.

Cornelius Los angeles, Nehring LC, Harding Age, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD: Matrix metalloproteinases make angiostatin: outcomes towards the neovascularization. J Immunol. 1998, 161 (12): 6845-6852.

Jiang Y, Goldberg ID, Shi YE: Advanced spots out-of muscle inhibitors away from metalloproteinases inside the malignant tumors. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.

Comments are closed.